Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2012

View Archived Issues

Studies yield encouraging VRS-317 pharmacodynamic and safety data

Pfizer immunotherapeutic for inflammatory diseases shows promise in phase I trials

Epicutaneous patch for peanut allergy safe and effective in patients

Michael J. Fox Foundation extends support to biomarker research program

Insmed doses first patient in TARGET-NTM trial

Investigators in Israel design new mouse model of familial dysautonomia

Vorinostat in combination with bortezomib: Final results from VANTAGE trials

FDA approves Astellas drug for overactive bladder

Anthera updates phase III blisibimod plans

Gilead submits NDA for elvitegravir

Merrimack adds third arm to phase III trial in metastatic pancreatic cancer

FDA grants priority review to NDA for regorafenib

Novel PARP inhibitors developed in China

New formylpeptide receptor ligands patented by Allergan

Lilly presents novel MAP kinase p38 inhibitors

Research at Pfizer yields novel potential antibacterial drugs

New notum-directed antibodies may be useful to treat osteoporosis

Novel potential cancer immunotherapy designed in Korea

Synta reports on interim analysis of GALAXY trial

FDA accepts Shionogi NDA for review

Sanwa and Fuji submit application for hyperuricemia and gout treatment in Japan

Compugen shows potential of another B7/CD28-like protein target

SymBio opens enrollment in Japanese rigosertib trial

Astellas' Gonax approved in Japan

Vertex Pharmaceuticals announces final phase II data on VX-809/Kalydeco combination

Oxis Turbuhaler approved in Japan in different formulations

Eisai and Toyama Chemical obtain approval in Japan for rheumatoid arthritis drug

Japanese authorities approve Inlyta tablets

Mitsubishi Tanabe drug approved for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...